18:00 EDT Pliant Therapeutics (PLRX) files $300M mixed securities shelf
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics price target lowered to $3 from $4 at Canaccord
- How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance
- Pliant Therapeutics price target lowered to $3 from $4 at Piper Sandler
- Pliant Therapeutics reports Q4 EPS (38c), consensus (38c)
- Pliant Therapeutics Extends Stockholder Rights Agreement Expiration